Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Smith+Nephew acquisition of Engage Surgical
We are advising Smith+Nephew on the transaction
ProKidney combination with Social Capital Suvretta Holdings Corp. III
We are advising ProKidney on the transaction
Convey Health Solutions acquisition of HealthSmart International
We are advising Convey Health Solutions on the transaction
Signify Health defeats bid for preliminary injunction in trade-secret dispute
We secured a favorable resolution of all claims on behalf of Signify
Biodesix $50 million at-the-market offering
The shares are listed on the Nasdaq Global Market
Legend Biotech $345 million follow-on offering
The shares are listed on the Nasdaq Global Select Market
Dynamics Special Purpose $601 million combination with Senti Biosciences
We are advising Dynamics, a SPAC, on the transaction
BeiGene RMB22.2 billion Shanghai IPO
The offering, equivalent to $3.5 billion, is the largest biotech IPO to date in 2021
Yonghe HK$1.49 billion IPO
The shares are listed on the HKEX
Merck $8 billion notes offering, including its debut sustainability debt
The offering includes five tranches of notes